(Q36117231)

12 August 2017

1 reference

title

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature (English)

1 reference

12 August 2017

main subject

Stevens–Johnson syndrome

1 reference

toxic epidermal necrolysis

inferred from title

1 reference

Erik Letko

1

1 reference

12 August 2017

Dean N Papaliodis

2

1 reference

12 August 2017

George N Papaliodis

3

1 reference

12 August 2017

Yassine J Daoud

4

1 reference

12 August 2017

A Razzaque Ahmed

5

1 reference

12 August 2017

C Stephen Foster

6

1 reference

12 August 2017

publication date

1 April 2005

1 reference

Annals of Allergy, Asthma & Immunology

12 August 2017

published in

1 reference

12 August 2017

volume

94

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

419-36; quiz 436-8, 456

1 reference

A NEW ERUPTIVE FEVER ASSOCIATED WITH STOMATITIS AND OPHTHALMIA

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

The so-called Stevens-Johnson syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Requiem for toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Erythema multiforme--response to corticosteroid.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Epidemiologic approaches to the study of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

HLA antigens in Stevens-Johnson syndrome with ocular involvement.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Episodic conjunctival inflammation after Stevens-Johnson syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Immune complexes in erythema multiforme and the Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Rapidly progressive bronchiolitis obliterans associated with Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Improved treatment of the Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Burn treatment for the unburned

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Drug-induced toxic epidermal necrolysis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Demonstration of basal cell immunofluorescence in drug-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Acute and chronic respiratory complications of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Impaired antigen presentation in toxic epidermal necrolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Involvement of macrophages in the pathology of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Erythema multiforme and toxic epidermal necrolysis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Carbamazepine ('Tegretol') and toxic epidermal necrolysis: report of three cases with histopathological observations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Mixed cryoglobulinemia, 125I C1q binding and skin immunofluorescence in erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Haematological disturbances and immune mechanisms in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Dermal and epidermal types of erythema multiforme. A histopathologic study of 24 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Erythema multiforme: clinical, histopathologic, and immunologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Staphylococcal scalded skin syndrome. Clinical features, pathogenesis, and recent microbiological and biochemical developments

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Gastrointestinal involvement complicating Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Erythema multiforme and nephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Renal disease associated with toxic epidermal necrolysis (Lyell's disease).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis: an eruption resembling scalding of the skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis (the scalded skin syndrome): A reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis. A review of 75 cases in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis. Rapid differentiation between staphylococcal- and drug-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis in a 6-week-old infant

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Survival after a second episode of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

A review of toxic epidermal necrolysis in Britain

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Fumigant-induced toxic epidermal necrolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

A case of contact dermatitis, erythema multiforme, and toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis from oil lamp fuel

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Stevens-Johnson syndrome associated with occupational exposure to trichloroethylene.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Contact toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

An analysis of graft-versus-host disease in Syrian hamsters. I. The epidermolytic syndrome: description and studies on its procurement

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Treatment of toxic epidermal necrolysis. Créteil's experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis. A step forward in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Esophageal stricture secondary to drug-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis. Report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Delayed hypersensitivity in ampicillin-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Elevated serum amylase in a case of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Sjögren-like syndrome after drug-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

The cellular source of creatine kinase in patients with toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Increased serum and blister fluid levels of creatine kinase in patients with toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Gelatinases in drug-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Idiosyncratic drug reactions: a mechanistic evaluation of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Burn unit management of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Burn therapy 1985: acute management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis. Unmuddying the waters

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Nutritional problems of the acute and chronic burn patient. Relevance to epidermolysis bullosa

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

1 reference

7 January 2021

Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Management of toxic epidermal necrolysis with a hydrogel dressing and fluidized-bead bed: report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Use of amnion for the treatment of Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Ocular Aftermath of Stevens-Johnson Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Gas-permeable scleral contact lens therapy in ocular surface disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Treatment of toxic epidermal necrolysis with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Acute life-threatening dermatologic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy"

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis due to rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Plasmapheresis in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Drug-induced toxic epidermal necrolysis treated with cyclosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Observations on drug-induced toxic epidermal necrolysis in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis with extensive mucosal erosions of the gastrointestinal and respiratory tracts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Elevated serum amylase in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Toxic epidermal necrolysis in a burn patient complicated by acute pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961112-X

7 January 2021

10.1016/S1081-1206(10)61112-X

Identifiers

DOI

1 reference

12 August 2017

1 reference